ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

The Bangladesh Journal of Pharmacology, published by the Bangladesh Pharmacological Society, is a leading platform dedicated to advancing knowledge in the field of pharmacology. With an ISSN of 1991-007X and an E-ISSN of 1991-0088, this open access journal has been making significant contributions to the field since its inception in 2006. Located at the Bangabandhu Sheikh Mujib Medical University in Dhaka, Bangladesh, the journal provides a vital resource for researchers, professionals, and students interested in pharmacology, toxicology, and pharmaceutics. As of 2023, the journal is categorized in the Q4 quartile for pharmacology, ranking 240th out of 313 in Scopus and falling within the 23rd percentile, reflecting its commitment to the dissemination of high-quality research. The journal encompasses a diverse array of topics from basic research to clinical applications, aiming to foster a deeper understanding of pharmacological principles and practices. By providing open access to its content, the Bangladesh Journal of Pharmacology ensures that valuable scientific findings are readily available to the global community, supporting the advancement of medical and pharmaceutical sciences.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.